Entvin AI, a provider of artificial intelligence services to pharma and life sciences companies globally, has officially launched out of beta and raised $500,000 in its first round of funding from Y Combinator.
The funds raised will be used to expand its artificial intelligence capabilities and accelerate customer acquisition among mid-to-large pharmaceutical companies globally.
Sanskar Jain, Co-founder and Chief Executive Officer of Entvin, said, “Regulatory professionals spend countless hours on documentation, compliance checks, and staying updated with constantly evolving FDA guidelines. Our artificial intelligence agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens.”
Hemant Phalak, Co-Founder & CPO, said, “At Entvin, our AI agents seamlessly integrate into existing workflows to enhance efficiency and accelerate decision-making. Our platform doesn’t just organize information – it actively identifies compliance gaps, automates repetitive documentation tasks, and provides regulatory teams with actionable insights in real-time. This helps life science companies navigate the approval process with unprecedented efficiency while maintaining trust, reliability and seamless integration.”
Rishabh Arya, Co-founder and Chief Technology Officer of Entvin, said, “We’ve developed an artificial intelligence system that deeply understands the complex language of FDA regulations and can process massive volumes of regulatory documentation. Our architecture is enterprise-grade, designed to meet the highest compliance standards required by pharmaceutical companies like SOC 2 and ISO 2700.”
Founded in 2022 by Sanskar Jain, Hemant Phalak, and Rishabh Arya, Entvin AI is an artificial intelligence platform that streamlines the time-consuming, resource-intensive and complex US Food and Drug Administration (FDA) drug approval process. The company has developed an AI platform to streamline these challenges.
Entvin’s artificial intelligence platform automates document drafting, compliance verification, and regulatory monitoring tasks. The platform’s technical architecture leverages large language models specifically fine-tuned for regulatory documentation and FDA compliance requirements.
